LSP 7 Cooperative UA 3
3 · Evommune, Inc. · Filed Nov 5, 2025
Insider Transaction Report
Form 3
Evommune, Inc.EVMN
LSP 7 Cooperative UA
Director10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (773,069 underlying)Series B Preferred Stock
→ Common Stock (646,587 underlying)Series A Preferred Stock
→ Common Stock (1,947,477 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ()"IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
- [F2]The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
- [F3]The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
- [F4]The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.